A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control

  • Kazutaka IijimaEmail author
  • Mitsuharu Oozeki
  • Kaori Ikeda
  • Hiroyuki Honda
  • Hajime Ishibashi
  • Masaharu Yamaoka
  • Shinji Fujieda
  • Hitoaki Saitoh
  • Mitsuhide Goto
  • Masahiro Araki
  • Kenji Amagai
Case Report


Small bowel adenocarcinomas are rare. There is no definite consensus as to whether they should be treated in a manner similar to gastric or to colon cancer. We report the case of a young woman with a primary jejunal adenocarcinoma, bilateral ovary metastases, and peritoneal dissemination. First- and second-line chemotherapy for the gastric cancer failed. She was then treated with the immune checkpoint inhibitor nivolumab and had temporary improvement in her condition. To the best of our knowledge, this is the first case wherein nivolumab has been used to treat small bowel adenocarcinoma.


Small bowel adenocarcinoma Signet ring cell carcinoma Immune checkpoint inhibitors 




Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interest.

Human/animal rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Neugut AI, Jacobson JS, Suh S, et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev. 1998;7:243–51.PubMedGoogle Scholar
  2. 2.
    Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973–1990. Int J Epidemiol. 1996;25:722–8.CrossRefGoogle Scholar
  3. 3.
    Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.CrossRefGoogle Scholar
  4. 4.
    Shenoy S. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol. 2016;8:509–19.CrossRefGoogle Scholar
  5. 5.
    Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46:97–104.CrossRefGoogle Scholar
  6. 6.
    Syngal S, Brand RE, Church JM, American College of Gastroenterology, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRefGoogle Scholar
  7. 7.
    Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119(06):1447–53.CrossRefGoogle Scholar
  8. 8.
    Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–43.CrossRefGoogle Scholar
  9. 9.
    Aparicio T, Zaanan A, Mary F, et al. Small bowel adenocarcinoma. Gastroenterol Clin North Am. 2016;45:447–57.CrossRefGoogle Scholar
  10. 10.
    Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res (Phila). 2011;4:1–5.CrossRefGoogle Scholar
  11. 11.
    Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.CrossRefGoogle Scholar
  12. 12.
    Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101:2826–32.CrossRefGoogle Scholar
  13. 13.
    Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRefGoogle Scholar
  14. 14.
    Takayoshi K, Kusaba H, Uenomachi M, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRefGoogle Scholar
  15. 15.
    Howe JR, Karnell LH, Menck HR, et al. Adenocarcinoma of the small bowel: review of the National Cancer Data Base. Cancer 1985-1995;86:2693–2706.Google Scholar
  16. 16.
    Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199:797–803.CrossRefGoogle Scholar
  17. 17.
    Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518–26.CrossRefGoogle Scholar
  18. 18.
    Umman P, Adiyodi V, Narayan C. Small bowel adenocarcinoma—report of two cases and review of literature. Indian J Surg. 2013;75:123–7.CrossRefGoogle Scholar
  19. 19.
    Hong SH, Koh YH, Rho SY, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39:54–61.CrossRefGoogle Scholar
  20. 20.
    Schwameis K, Schoppmann SF, Stift J, et al. Small bowel adenocarcinoma—terra incognita: a demand for cross-national pooling of data. Oncol Lett. 2014;7:1613–7.CrossRefGoogle Scholar
  21. 21.
    Lech G, Korcz W, Kowalczyk E, et al. Primary small bowel adenocarcinoma: current view on clinical features, prognostic factors, treatment and outcome. Scand J Gastroenterol. 2017;52:1194–202.CrossRefGoogle Scholar
  22. 22.
    Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–603.CrossRefGoogle Scholar
  23. 23.
    Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs. 2012;23:561–6.CrossRefGoogle Scholar
  24. 24.
    Clinical Practice Guidelines in Oncology Colon cancer version 1.2019-March 15,2019. ( Accessed 2019 March 28.
  25. 25.
    Kotoe T, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80:333–42.CrossRefGoogle Scholar
  26. 26.
    Gulhati P, Raghav K, Shroff R, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist. 2018;23:277e26.CrossRefGoogle Scholar
  27. 27.
    Otsuji E, Yamaguchi T, Sawai K, et al. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol. 1998;67:216–20.CrossRefGoogle Scholar
  28. 28.
    Makino T, Mishima H, Ikenaga M, et al. Clinicopathologic features of signet-ring cell carcinoma of the colon and rectum. Jpn J Gastroenterol Surg. 2006;39:16–22.CrossRefGoogle Scholar
  29. 29.
    Liu An-Chieh, Chen Ch, et al. A rare Krukenberg tumor arising from a primary adenocarcinoma of the small intestine. Taiwan J Obstet Gynecol. 2018;57(2):319–22.CrossRefGoogle Scholar
  30. 30.
    Woodruff JD, Novak ER. The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol. 1960;15:351–60.PubMedGoogle Scholar
  31. 31.
    Mitsushita J, Tanaka A, et al. Metastatic ovarian tumors originating from a small bowel adenocarcinoma–a case report and brief literature review. Int J Gynecol Pathol. 2017;36(3):253–60.CrossRefGoogle Scholar
  32. 32.
    Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.CrossRefGoogle Scholar
  33. 33.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5).Google Scholar
  34. 34.
    Shahabi V, Postow MA, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38(1):90–7.CrossRefGoogle Scholar
  35. 35.
    Seyedin SN, Schoenhals JE, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967–80.CrossRefGoogle Scholar
  36. 36.
    Hecht MI, Büttner-Herold M, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.CrossRefGoogle Scholar
  37. 37.
    De Wolf K, Kruse V, et al. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;31;15(1):21.Google Scholar
  38. 38.
    Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.CrossRefGoogle Scholar
  39. 39.
    Kim ST, Cristescu R, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Kazutaka Iijima
    • 1
    • 2
    Email author
  • Mitsuharu Oozeki
    • 1
  • Kaori Ikeda
    • 1
  • Hiroyuki Honda
    • 1
  • Hajime Ishibashi
    • 1
  • Masaharu Yamaoka
    • 1
  • Shinji Fujieda
    • 1
  • Hitoaki Saitoh
    • 3
  • Mitsuhide Goto
    • 1
  • Masahiro Araki
    • 1
  • Kenji Amagai
    • 1
  1. 1.Department of GastroenterologyIbaraki Prefectural Central HospitalKasama-CityJapan
  2. 2.Department of GastroenterologyRumoi Municipal HospitalHokkaidoJapan
  3. 3.Department of Diagnostic PathologyIbaraki Prefectural Central HospitalIbarakiJapan

Personalised recommendations